Related to Are Early Clinical Successes Enough to Bring RNAi Back from the Brink?

• SurModics and Egen Extend Partnership to Study Long-Term Delivery of siRNAs
  
• Isis Earns $5M Milestone from GSK Five Months into RNA Therapeutics Partnership
  
• Novartis Shells Out $10M for Option to Quark’s Phase II-Stage Synthetic siRNA
  
• RXi and EyeGate Join Forces for Noninvasive Ocular Delivery of RNAi Therapeutics
  
• Alnylam to Nix Jobs in the Wake of Novartis Collaboration Ending
  
• Tekmira Nabs License to Alnylam IP to Develop Ebola Virus Therapy Funded by U.S. Govt
  
• Arrowhead Inks Deals that Focus Firm on Nanomedicines
  
• Lundbeck and UMMS to Evaluate RNAi-Based Drug for Huntington Disease
  
• Debiopharm and Marina Partner to Develop Bladder Cancer RNAi Therapeutic
  
• Alnylam Extends RNAi Alliance with UBC and AlCana Technologies
  
• Precision NanoSystems and Alnylam Ally to Enhance RNAi Delivery
  
• Alnylam to Test Molecular Templates’ Technology for RNAi Drug Delivery
  
• BMS Expands Deal to Evaluate Tekmira’s RNAi Delivery Technology
  
• Researchers Claim Blocking Cdk1 Makes Wild-Type BRCA1 Cancers Susceptible to PARP Inhibition
  
• Zinc Finger-Based Approach Rectifies Clotting Times in Mice with Hemophilia B
  
• Thermo Fisher Scientific Offers siRNA Reagent Libraries via Labcyte Echo® Qualified Plates
  
• RXi Restructures to Focus on Cancer and Spins Out RNAi Therapeutics
  
• Chemokine Receptor-Targeting siRNA Nanoparticles Used to Reduce Damage in Multiple Disease Models
  
• Ablitech Gets $2M DoD Grant for R&D into Heterotopic Ossification
  
• Roche Gives Arrowhead RNAi Assets and Facility in Madison, WI